Upregulation of Antioxidant Enzymes by ASS234, a Multitarget Directed Propargylamine for Alzheimer's Disease Therapy

CNS Neurosci Ther. 2016 Sep;22(9):799-802. doi: 10.1111/cns.12590. Epub 2016 Jul 6.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease / drug therapy*
  • Animals
  • Catalase / genetics
  • Catalase / metabolism
  • Cholinesterase Inhibitors / chemistry
  • Cholinesterase Inhibitors / therapeutic use*
  • Humans
  • Indoles / chemistry
  • Indoles / therapeutic use*
  • Pargyline / analogs & derivatives
  • Pargyline / therapeutic use
  • Piperidines / chemistry
  • Piperidines / therapeutic use*
  • Propylamines / therapeutic use
  • Signal Transduction / drug effects
  • Superoxide Dismutase-1 / genetics
  • Superoxide Dismutase-1 / metabolism
  • Up-Regulation / drug effects*

Substances

  • Cholinesterase Inhibitors
  • Indoles
  • N-((5-(3-(1-benzylpiperidin-4-yl)propoxy)-1-methyl-1H-indol-2-yl)methyl)-N-methylprop-2-yn-1-amine
  • Piperidines
  • Propylamines
  • propargylamine
  • Pargyline
  • Catalase
  • Superoxide Dismutase-1